SRR2016968
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.300
- PANCREAS_BETA_CELLS+0.270
- E2F_TARGETS+0.180
- G2M_CHECKPOINT+0.130
- MYC_TARGETS_V1+0.130
- HEDGEHOG_SIGNALING+0.110
- MITOTIC_SPINDLE+0.110
- MYC_TARGETS_V2+0.110
- INTERFERON_GAMMA_RESPONSE+0.100
- KRAS_SIGNALING_DN+0.090
Top 10 suppressed
- ANGIOGENESIS-0.380
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.370
- TGF_BETA_SIGNALING-0.360
- MYOGENESIS-0.300
- P53_PATHWAY-0.300
- APICAL_JUNCTION-0.290
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.290
- CHOLESTEROL_HOMEOSTASIS-0.280
- COAGULATION-0.280
- APICAL_SURFACE-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E7-A6ME-01A-22R-A32O-07 | — | — | 0.850 |
| 2 | C3N-02728 | — | cohortMD1 | 0.828 |
| 3 | SAMN03290898 | — | — | 0.811 |
| 4 | MNG182 | — | — | 0.809 |
| 5 | BS_M1T1K5WV | EPN | EPN Tumor | 0.807 |
| 6 | SRR25617852 | — | B | 0.803 |
| 7 | TCGA-GV-A3QH-01A-11R-A220-07 | — | — | 0.795 |
| 8 | TCGA-85-A510-01A-11R-A26W-07 | — | cohortA3 | 0.793 |
| 9 | SRR4195674 | — | — | 0.793 |
| 10 | BS_7FWZ518S | medulloblastoma | — | 0.789 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.270 | Cobimetinib | — uncovered |
| E2F_TARGETS | 0.180 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.130 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.130 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.110 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.110 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.110 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.080 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |